BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference

From Startup Brainstorm Cell Therapeutics

Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2366181

Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET
NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwright & Co. 20th Annual Investor Conference, on Thursday, September 6th at 2:10pm Eastern Time, instead of the previously announced time of 5:00pm.
Presentation Details:Date:                           Thursday, September 6Time:                           2:10pm Eastern Time (previously scheduled for 5:00pm Eastern Time)Location:                     Louis XVI B room, St. Regis Hotel, New York.  Speaker:                      Ralph Kern, MD., MHSc., Chief Operating and Chief Medical OfficerWebcast:                     http://wsw.com/webcast/rrshq28/bcli/index.aspx
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 100 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the US, a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the Company’s website at www.brainstorm-cell.com.
CONTACTSMedia:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com 
Investors:Michael RiceLifeSci Advisors, LLCPhone: 646-597-6979mrice@lifesciadvisors.com

BrainStorm Cell Therapeutics Inc.

Please visit their site for more information: Brainstorm Cell Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-09-06 05:32:49